Humana (HUM) Stock Surges 12% As Medicare Rate Blows Past Wall Street Expectations

TLDR

• The Centers for Medicare and Medicaid Services (CMS) finalized a 2.48% Medicare Advantage rate increase for 2027, far above the 0.09% proposed in January.
• Humana (HUM) jumped 12% after hours, while UnitedHealth (UNH) and CVS Health (CVS) rose over 6% in premarket trading.
• The final rate translates to over $13 billion in additional Medicare Advantage payments to insurers in 2027.
• Hospital and managed care stocks also rallied, with Molina Healthcare (MOH) up 7% and Centene (CNC) rising 4%.
• Mizuho analyst Jared Holz said the rate is “certainly better than the government’s initial rate decision,” but noted it’s not exceptional on its own.

💥 Find the Next KnockoutStock! Get live prices, charts, and KO Scores from KnockoutStocks.com, the data-driven platform ranking every stock by quality and breakout potential.

Humana (HUM) opened up around 11% on Tuesday following Monday’s after-hours announcement of the final 2027 Medicare Advantage payment rates.

Humana Inc., HUM

The final rate of 2.48% is a major step up from the 0.09% proposed rate in January, which caught the industry off guard and sent insurer stocks lower at the time.

The CMS announcement means private health insurers will collect more than $13 billion in additional Medicare Advantage payments from the government in 2027.

UnitedHealth (UNH) and CVS Health (CVS), parent of Aetna, both gained more than 6% in premarket Tuesday. Elevance Health (ELV) climbed around 5%. Hospital and managed care names also caught a bid, with Molina Healthcare (MOH) up 7% and Centene (CNC) rising 4%.

The jump in these stocks came after months of lobbying from insurers and their trade groups, who argued the January proposal did not reflect rising medical costs. The Better Medicare Alliance had called the near-zero initial proposal a functional “cut,” pointing to medical cost trends running at 7% to 9% annually.

What Changed in the Final Rate

CMS made several technical updates alongside the headline rate. Starting in 2027, the agency will exclude diagnosis data from unlinked chart review records when calculating risk scores, with a carve-out for beneficiaries switching between Medicare Advantage organizations.

The agency said this change will have a bigger impact on plans that rely heavily on those chart reviews to document patient diagnoses and collect higher payments. CMS also updated the Part D risk adjustment model to account for changes under the Inflation Reduction Act.

CMS Administrator Dr. Mehmet Oz said the updates aim to keep “coverage affordable” and ensure patients get “real value from their plans.”

Wall Street had been cautious heading into Monday’s announcement. TD Cowen’s Ryan Langston had penciled in a more modest bump in the 1% to 1.5% range. The 2.48% outcome exceeded those expectations, though Mizuho’s Jared Holz tempered enthusiasm: “We do not believe a Medicare rate increase of 2.5% is so awesome in a vacuum, but is certainly better than the government’s initial rate decision.”

Holz said there is now “a chance for margins to expand next year, provided the Companies continue to trim benefits and align costs with revenue.”

The Stakes Behind the Rate

Medicare Advantage covers around 35 million beneficiaries and has grown steadily to surpass enrollment in traditional government-run Medicare. The final rate governs how more than half a trillion dollars flows through private health plans each year, making it one of the most closely watched data points in the health insurance sector.

The rate includes factors such as underlying cost growth, 2026 Star Ratings for quality bonus payments, and risk adjustment methodology updates. CMS confirmed it will continue using the 2024 Medicare Advantage risk adjustment model for 2027.

Bipartisan pressure to rein in Medicare Advantage spending had added uncertainty to the process. Both parties have raised questions about insurer coding practices that can lead to higher payments for patients with more recorded diagnoses. The Biden-era CMS had already started tightening those payments, and the January proposal under the Trump administration signaled that scrutiny would continue.

Considering a new stock? You may want to see what’s on our watchlist first.

Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.

✨ Limited Time Offer

Get 3 Free Stock Ebooks

            Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
        

        

            *                       
                    **Top 10 AI Stocks** - Leading AI companies
                
            *                       
                    **Top 10 Crypto Stocks** - Blockchain leaders
                
            *                       
                    **Top 10 Tech Stocks** - Tech giants
                
        

        

            
                📥 Get Your Free Ebooks